Jefferies Maintains Bullish Stance On Questcor (QCOR) Following Meeting

Jefferies reiterated its Buy rating and $52 price target on Questcor Pharmaceuticals (NASDAQ: QCOR) following feedback from the National Kidney Foundation Spring meeting.

The firm comments, "Based on our interactions with nephrologists on-site at the National Kidney Foundation Spring meeting, we continue to believe NS remains significantly underpenetrated for Acthar on both mkt share and mindshare. QCOR's recent expansion in its NS mktg efforts is timely for improving product awareness, potentially translating to increased adoption and sales growth."

For an analyst ratings summary and ratings history on Questcor Pharmaceuticals click here. For more ratings news on Questcor Pharmaceuticals click here.

Shares of Questcor Pharmaceuticals closed at $41.13 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
• HSBC Upgrades Topdanmark (TOP:DC) (TPDKY) to Hold
• Boston Beer Company (SAM) PT Lowered to $310 at Evercore ISI